ENGLEWOOD CLIFFS, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. (Nasdaq: ATLN), a leading provider of strategic staffing outsourced services and workforce solutions, today announced that its subsidiary Lyneer Staffing Solutions has successfully renewed its partnership with the premier food production company, first announced in October 2024. This renewal comes with a significant strategic advantage: the client's decision to consolidate its staffing partnerships from three providers to ...

Strategic consolidation positions Lyneer for significant revenue growth, targeting $12+ million annuallyENGLEWOOD CLIFFS, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. (Nasdaq: ATLN), a leading provider of strategic staffing outsourced services and workforce solutions, today announced that its subsidiary Lyneer Staffing Solutions has successfully renewed its partnership with the premier food production company, first announced in October 2024. This renewal comes with a significant str ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 reached $9.3 million, representing an 86% year-over-year increase [5][6] - First half revenues totaled $17.3 million, which is 89% of the entire 2024 fiscal year total of $19.54 million [6][23] - Adjusted EBITDA for Q2 was $1.6 million, a 134% year-over-year increase, with first half adjusted EBITDA reaching $2.8 million [24] - Pretax income for Q2 more than doubled year-over-year to $800,000, with first half pretax income at $1.5 million [24][25] - Cash flow from operating activities was positive $1.5 million in Q2, with total cash flow for all activities at positive $600,000 [29] Business Line Data and Key Metrics Changes - The company expanded its distribution network to 778 partners, an 87% increase year-over-year [7] - Billed enrolled employees increased by 30%, reaching 24,839 [7] - Sales and marketing expenses were $1.2 million for the quarter, a 6.3% reduction year-over-year [27] - General administrative expenses were $3.8 million, a 4.2% increase compared to the same period last year [28] Market Data and Key Metrics Changes - The company is focusing on small and mid-sized employers, with a significant market opportunity remaining as it has only captured a small fraction of the potential market [87] - The healthcare insurance market is characterized by uncertainty, presenting opportunities for the company to provide alternatives [89][90] Company Strategy and Development Direction - The company is broadening its market reach through strategic partnerships with third-party administrators and regional healthcare benefit providers [7][10] - The enhanced eDiP platform is set to launch fully in Q3, with new product offerings expected to be beta tested by the end of Q3 [11] - The company aims to maintain strong growth momentum through technology enhancement and product innovation [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to maintain growth momentum despite the typically slow sales seasons [9] - The current healthcare market's challenges, including rising rates from ACA carriers, create opportunities for the company to offer solutions [91][92] Other Important Information - The company is actively working on the HiCard project, with expectations to see revenue from it in Q1 of the following year [66][67] - The company is exploring new product opportunities and will announce them as they approach completion [72][74] Q&A Session Summary Question: How is the company benefiting from partnerships? - Management noted that partnerships allow for more distribution opportunities and can lead to new employer clients [55] Question: How is the company targeting mid-sized employers? - The company is not actively marketing to large employers but is seeing an uptick in requests from larger groups through broker partners [42][44] Question: What is the company's approach to controlling expenses? - Management emphasized disciplined expense management and the expectation that revenue growth will outpace expense growth [63][64] Question: What is the outlook for the HiCard project? - The HiCard project is expected to be implemented by August, with revenue anticipated in Q1 of the following year [66][67] Question: How does the company view the current healthcare insurance market? - Management sees the current uncertainty in the market as a significant opportunity to provide alternatives and solutions [89][90]

Core Viewpoint - Moleculin Biotech, Inc. has appointed Adriano Treve as a Strategic Advisor for partnerships, leveraging his extensive experience in global healthcare to enhance the company's strategic positioning and partnership opportunities as it advances its clinical trials [1][3][5]. Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat cancers and viral infections [1]. - The company's lead program, Annamycin, is designed to avoid multidrug resistance and cardiotoxicity associated with current anthracyclines, targeting relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma [10][11]. Key Developments - The Phase 2B/3 MIRACLE trial for Annamycin in combination with cytarabine is ongoing, with the first unblinding of data for 45 patients expected in the second half of 2025 and a second unblinding anticipated in the first half of 2026 [4][8]. - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for treating relapsed or refractory AML, as well as similar designations from the EMA [9]. Strategic Partnerships - Mr. Treve's appointment is expected to enhance Moleculin's ability to secure partnerships that could optimize the value of Annamycin, which has the potential to significantly impact the global oncology drug market [5][6]. - The company is experiencing increased interest from potential strategic partners as it approaches key milestones in its clinical trials [6]. Clinical Trial Details - The MIRACLE trial is a pivotal, adaptive design Phase 3 study evaluating Annamycin in combination with cytarabine for adult patients with relapsed or refractory AML, conducted across multiple sites in the US, Europe, and the Middle East [11]. - The trial follows a successful Phase 1B/2 study, which has de-risked the development pathway towards potential approval for Annamycin [11].

Financial Data and Key Metrics Changes - The company recorded total revenue of $34.2 million for the quarter, remaining in line compared to the same quarter last year [23] - Gross profit for the first quarter was $4.8 million, or 14% of revenues, compared to $4.7 million, or 14% of revenues in the same period in 2024 [25] - Net loss for the first quarter was $724,000, or a loss of $0.08 per share, compared to a net loss of $653,000, or a loss of $0.07 per share for the same period last year [27] - Adjusted EBITDA for the first quarter was $92,400, marking the thirty-first consecutive quarter of positive adjusted EBITDA [27] Business Line Data and Key Metrics Changes - Carrier services revenue for the quarter was $22.4 million, an increase of $3 million compared to the same period in 2024, driven by growth in the number of lines under management for the DHS customer [24] - Managed services fees for the quarter were $9.3 million, an increase of $564,000 compared to the same period last year, primarily due to a new federal end customer [24] - Reselling and other services revenue decreased to $789,000, a drop of $4.2 million from the same period last year, with $2.7 million of the decrease attributed to an out-of-period adjustment [25] Market Data and Key Metrics Changes - The federal contract backlog as of March 31, 2025, stood at $268 million, indicating a strong pipeline of future revenue opportunities [25] - The company is experiencing increased activity under the SPIRO-four contract, with two additional task orders awarded this quarter [6][7] Company Strategy and Development Direction - The company aims to deepen relationships with existing partners while building new ones, particularly through its Device as a Service initiative [11] - The company plans to prepare for the upcoming DHS CWMS three point zero recompete, believing it is well-positioned to win the contract again [11] - Strategic investments will be made in sales and marketing capabilities to drive visibility and growth across core markets [20] Management's Comments on Operating Environment and Future Outlook - Management remains cautiously optimistic about the alignment with federal government priorities, particularly in reducing waste and improving efficiency [9] - The company is focused on capturing opportunities in a politically dynamic and economically uncertain environment, with a commitment to delivering long-term value for shareholders [12] - Management expressed confidence in achieving positive earnings per share for 2025, despite the ongoing economic challenges [12] Other Important Information - The company plans to increase capital investments by approximately $500,000 for the year to support strategic priorities, including the Device as a Service program [28] - The cash balance at the end of the quarter was $3.7 million, impacted by administrative challenges with a major customer [28] Q&A Session Summary Question: Clarification on accounting adjustment impact - The analyst inquired if the reported numbers should be adjusted to reflect the out-of-period adjustment, to which the CFO confirmed that revenue and EBITDA should be grossed up accordingly [31][32] Question: Timeline for CWMS recompete - Management indicated that the recompete is expected to occur this year, with an award made prior to the expiration of the current contract in November [35][36] Question: Details on SPIRO-four contract - Management confirmed that SPIRO-four has a total contract value of $2.7 billion, with the company having captured several task orders under this contract [41][42] Question: Commercial opportunities and resource allocation - Management highlighted that there are significant commercial opportunities, particularly in the Device as a Service sector, and emphasized ongoing investments to support these initiatives [57][58]

Financial Data and Key Metrics Changes - Total revenue for the first quarter was $13.9 million, a slight increase of 2.2% from $13.6 million in the prior year [16] - Gross profit for the quarter was $657,000, compared to a gross loss of $620,000 in Q1 of the previous year [17] - Net loss for the quarter remained consistent at $3.6 million, with a loss per share of $0.19 compared to $0.26 in the prior year [17][18] Business Segment Data and Key Metrics Changes - Treatment Segment revenue increased by $477,000 or 5.5% year over year, driven by higher waste volumes received and processed [16] - Services Segment revenue decreased by $175,000 due to delays in federal procurement activity [16][8] - Gross profit in the Treatment Segment improved due to higher revenue and lower variable costs, while the Services Segment saw a significant improvement in gross margins [17][8] Market Data and Key Metrics Changes - Waste backlog grew to over $10 million, up approximately 30% from the previous year [6][19] - International waste receipts improved, with approximately $7 million worth of waste received from Canada, Mexico, and Germany [11] Company Strategy and Development Direction - The company is focusing on expanding its PFAS program, which is seen as a long-term growth driver due to increasing state regulations [9] - Strategic partnerships are being developed to enhance international presence and diversify revenue streams [13] - The company anticipates stronger performance in the second half of 2025, supported by key growth drivers including waste treatment backlog and federal procurement visibility [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the federal budget, indicating no significant cuts to the Hanford project and potential increases in funding for waste remediation [23][24] - The company is seeing a significant increase in waste receipts from Hanford, with expectations of continued treatment for several years [26][28] - Management remains confident in the upcoming DF Law program and its potential to generate high-margin recurring revenue [10] Other Important Information - The company is making targeted investments to support new waste receipts, including staffing and facility readiness [7] - The new EPA Administrator's focus on PFAS remediation is viewed positively, potentially driving demand for the company's technology [10][42] Q&A Session Summary Question: Impact of the 2026 federal budget on 2025 and 2026 - Management noted that the proposed budget is favorable, with no reduction in Hanford funding and a significant increase in the NNSA side, which could lead to more remediation projects [23][24] Question: Current waste receipts from Hanford - Management confirmed receiving $2 million to $3 million a month from Hanford, significantly higher than in the past [26] Question: Margins from Hanford contracts - Management refrained from discussing specific margins but emphasized traditional margins and cost management efforts [27] Question: Update on grouting and near-term priorities - Management indicated that DOE is expected to provide clarity on their strategy by December 2025, with optimism about the company's role in the grouting program [35][36] Question: Contribution from the second-generation PFAS unit - Management expects the new system to generate approximately $1 million a month initially, with long-term goals of $20 million a year [39][40] Question: Status of services and RFPs - Management reported an increase in project opportunities and a clearer path forward for the West Valley project, with expectations for more clarity in the coming months [44][47] Question: CapEx priorities for the year - Management anticipates CapEx in the range of $5 million to $6 million, focusing on sustaining operations and the second-generation reactor [48] Question: Commentary on competition and market dynamics - Management acknowledged competition but expressed confidence in securing a significant portion of the waste due to local operations and community ties [84]

Core Viewpoint - Choice Hotels International, Inc. (CHH) is experiencing growth driven by steady unit expansion, a strong global pipeline, and rising demand across its portfolio, although concerns about the macroeconomic environment persist [1] Growth Catalysts for CHH Stock - Solid business travel demand is evident, with business travel accounting for approximately 40% of total revenues in 2024 and a 14% growth in the business transient segment in Q4 [2] - Continued strength in business travel is expected for 2025, supported by higher group bookings and sustained demand in the business transient segment [3] - The company is effectively executing its unit growth strategy, focusing on both domestic and international expansion [3] Development and Pipeline - In 2024, CHH achieved a 36% year-over-year increase in domestic upscale franchise agreements awarded, with a global pipeline of 964 hotels (approximately 97,325 rooms) as of December 31, 2024 [4] - About 88% of the pipeline is located in the United States, with nearly 71% dedicated to new construction projects [4] Strengthening Rewards and Partnerships - The rewards program grew to 69 million members in 2024, reflecting an 8% year-over-year increase, marking the highest organic enrollment in a year [6] - Strategic partnerships, including a collaboration with Westgate Resorts, added over 14,000 rooms to the domestic portfolio, enhancing offerings [6] Concerns for Choice Hotels Stock - Despite outperforming the Zacks Hotels and Motels industry year-to-date, CHH stock has declined by 12%, while the industry saw a drop of 16.8%, primarily due to market volatility and discretionary spending concerns [10] - Uncertain financial conditions, rising interest rates, and intense competition are additional challenges facing the company [11]

Core Viewpoint - Massimo Motor is actively engaging with retail partners through participation in industry events to enhance relationships and gain insights into customer preferences and market trends [1][2][4]. Company Engagement - Massimo Motor participated in the Rural King Vendor Summit and is attending the Tractor Supply Company & PetSense ASM and Partner Trade Show, which are critical for collaboration with retail partners [1][2]. - The company emphasizes the importance of listening and learning from retail partners to refine product offerings and meet customer expectations [2][3]. Market Positioning - The shared customer base between Massimo, Rural King, and Tractor Supply focuses on practicality, value, and high-quality equipment, reinforcing Massimo's commitment to serving farmers, ranchers, and outdoor enthusiasts [3][4]. - Massimo's proactive approach to market expansion and strategic growth is highlighted by strengthening partnerships with established retail leaders, ensuring competitive and accessible products [4]. Product Focus - Massimo Motor specializes in manufacturing UTVs, ATVs, and outdoor equipment, aiming to deliver high-performance, durable, and affordable solutions tailored for rural communities and outdoor enthusiasts [5].